

SUPPLEMENTARY APPENDIX

1. *Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. The European FK 506 Multicentre Psoriasis Study Group.* Arch Dermatol, 1996. **132**(4): p. 419-23.
2. *The International Psoriasis Genetics Study: assessing linkage to 14 candidate susceptibility loci in a cohort of 942 affected sib pairs.* Am J Hum Genet, 2003. **73**(2): p. 430-7.
3. Abrams, J.R., et al., *Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells.* J Exp Med, 2000. **192**(5): p. 681-94.
4. Ackermann, L., et al., *Mast cells in psoriatic skin are strongly positive for interferon-gamma.* Br J Dermatol, 1999. **140**(4): p. 624-33.
5. Aggarwal, B.B., *Signalling pathways of the TNF superfamily: a double-edged sword.* Nat Rev Immunol, 2003. **3**(9): p. 745-56.
6. Aggarwal, B.B., et al., *The role of TNF and its family members in inflammation and cancer: lessons from gene deletion.* Curr Drug Targets Inflamm Allergy, 2002. **1**(4): p. 327-41.
7. Aggarwal, S., et al., *Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17.* J Biol Chem, 2003. **278**(3): p. 1910-4.
8. Alarcon-Riquelme, M.E., *A RUNX trio with a taste for autoimmunity.* Nat Genet, 2003. **35**(4): p. 299-300.
9. Albanesi, C., et al., *Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma- and interleukin-4-induced activation of human keratinocytes.* J Invest Dermatol, 2000. **115**(1): p. 81-7.
10. Alegre, M.L., K.A. Frauwirth, and C.B. Thompson, *T-cell regulation by CD28 and CTLA-4.* Nat Rev Immunol, 2001. **1**(3): p. 220-8.
11. Allen, M., et al., *Corneodesmosin expression in psoriasis vulgaris differs from normal skin and other inflammatory skin disorders.* Lab Invest, 2001. **81**(7): p. 969-76.
12. Anton van der Merwe, P., et al., *Cytoskeletal polarization and redistribution of cell-surface molecules during T cell antigen recognition.* Semin Immunol, 2000. **12**(1): p. 5-21.
13. Antoni, C. and B. Manger, *Infliximab for psoriasis and psoriatic arthritis.* Clin Exp Rheumatol, 2002. **20**(6 Suppl 28): p. S122-5.
14. Arason, G.J., et al., *Deficiency of complement-dependent prevention of immune precipitation in systemic sclerosis.* Ann Rheum Dis, 2002. **61**(3): p. 257-60.
15. Asadullah, K., et al., *Interleukin-10 promoter polymorphism in psoriasis.* J Invest Dermatol, 2001. **116**(6): p. 975-8.
16. Asadullah, K., et al., *IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach.* J Clin Invest, 1998. **101**(4): p. 783-94.

17. Austin, L.M., et al., *The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type I cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type I differentiation bias is also measured in circulating blood T cells in psoriatic patients.* J Invest Dermatol, 1999. **113**(5): p. 752-9.
18. Bagel, J., et al., *Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial.* J Am Acad Dermatol, 1998. **38**(6 Pt 1): p. 938-44.
19. Baker, B.S., et al., *Skin T cell proliferative response to M protein and other cell wall and membrane proteins of group A streptococci in chronic plaque psoriasis.* Clin Exp Immunol, 2001. **124**(3): p. 516-21.
20. Baker, B.S., et al., *The effects of cyclosporin A on T lymphocyte and dendritic cell sub-populations in psoriasis.* Br J Dermatol, 1987. **116**(4): p. 503-10.
21. Banchereau, J. and R.M. Steinman, *Dendritic cells and the control of immunity.* Nature, 1998. **392**(6673): p. 245-52.
22. Barker, J.N., *The pathophysiology of psoriasis.* Lancet, 1991. **338**(8761): p. 227-30.
23. Barker, J.N., et al., *Detection of interferon-gamma mRNA in psoriatic epidermis by polymerase chain reaction.* J Dermatol Sci, 1991. **2**(2): p. 106-11.
24. Barker, J.N., et al., *Keratinocytes as initiators of inflammation.* Lancet, 1991. **337**(8735): p. 211-4.
25. Barker, J.N., et al., *Marked synergism between tumor necrosis factor-alpha and interferon-gamma in regulation of keratinocyte-derived adhesion molecules and chemotactic factors.* J Clin Invest, 1990. **85**(2): p. 605-8.
26. Basu, S., et al., *CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin.* Immunity, 2001. **14**(3): p. 303-13.
27. Berkowitz, E.Z. and M. Lebwohl, *Cutaneous manifestations of inflammatory bowel disease.* J Eur Acad Dermatol Venereol, 2000. **14**(5): p. 349-50.
28. Beswick, T.S., *Robert Willan: the solution of a ninety-year-old mystery.* J Hist Med Allied Sci, 1957. **12**(3): p. 349-65.
29. Bhalerao, J. and A.M. Bowcock, *The genetics of psoriasis: a complex disorder of the skin and immune system.* Hum Mol Genet, 1998. **7**(10): p. 1537-45.
30. Blumberg, H., et al., *Interleukin 20: discovery, receptor identification, and role in epidermal function.* Cell, 2001. **104**(1): p. 9-19.
31. Boehncke, W.H., et al., *Pulling the trigger on psoriasis.* Nature, 1996. **379**(6568): p. 777.
32. Boehncke, W.H., et al., *Antagonistic effects of the staphylococcal enterotoxin a mutant, SEA(F47A/D227A), on psoriasis in the SCID-hu xenogeneic transplantation model.* J Invest Dermatol, 2001. **116**(4): p. 596-601.
33. Boehncke, W.H., et al., *The SCID-hu xenogeneic transplantation model allows screening of anti-psoriatic drugs.* Arch Dermatol Res, 1999. **291**(2-3): p. 104-6.
34. Bonish, B., et al., *Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells.* J Immunol, 2000. **165**(7): p. 4076-85.
35. Bos, J.D., *The pathomechanisms of psoriasis; the skin immune system and cyclosporin.* Br J Dermatol, 1988. **118**(2): p. 141-55.

36. Bowcock, A.M., et al., *Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies*. Hum Mol Genet, 2001. **10**(17): p. 1793-805.
37. Boyman, O., et al., *Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-{alpha}*. J Exp Med, 2004. **199**(5): p. 731-736.
38. Boyman, O., et al., *Induction of psoriasis involves TNF-a production by heat shock protein receptor CD91 expressing antigen presenting cells, and is independent on recruitment of lymphocytes*. J Invest Dermatol, 2002. **119**: p. 737.
39. Bromley, S.K., et al., *The immunological synapse*. Annu Rev Immunol, 2001. **19**: p. 375-96.
40. Brown, D.W., et al., *Skin CD4+ T cells produce interferon-gamma in vitro in response to streptococcal antigens in chronic plaque psoriasis*. J Invest Dermatol, 2000. **114**(3): p. 576-80.
41. Burden, A.D., et al., *Genetics of psoriasis: paternal inheritance and a locus on chromosome 6p*. J Invest Dermatol, 1998. **110**(6): p. 958-60.
42. Capon, F., et al., *Searching for the major histocompatibility complex psoriasis susceptibility gene*. J Invest Dermatol, 2002. **118**(5): p. 745-51.
43. Capon, F., et al., *Searching for psoriasis susceptibility genes in Italy: genome scan and evidence for a new locus on chromosome 1*. J Invest Dermatol, 1999. **112**(1): p. 32-5.
44. Capon, F., et al., *Haplotype analysis of distantly related populations implicates corneodesmosin in psoriasis susceptibility*. J Med Genet, 2003. **40**(6): p. 447-52.
45. Chang, J.C., et al., *Persistence of T-cell clones in psoriatic lesions*. Arch Dermatol, 1997. **133**(6): p. 703-8.
46. Changelian, P.S., et al., *Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor*. Science, 2003. **302**(5646): p. 875-8.
47. Cooley, H.M., et al., *Outcome of rheumatoid arthritis and psoriasis following autologous stem cell transplantation for hematologic malignancy*. Arthritis Rheum, 1997. **40**(9): p. 1712-5.
48. Curry, J.L., et al., *Innate immune-related receptors in normal and psoriatic skin*. Arch Pathol Lab Med, 2003. **127**(2): p. 178-86.
49. Curry, J.L., et al., *Reactivity of resident immunocytes in normal and prepsoriatic skin using an ex vivo skin-explant model system*. Arch Pathol Lab Med, 2003. **127**(3): p. 289-96.
50. Dam, T.N., et al., *1alpha,25-dihydroxycholecalciferol and cyclosporine suppress induction and promote resolution of psoriasis in human skin grafts transplanted on to SCID mice*. J Invest Dermatol, 1999. **113**(6): p. 1082-9.
51. Djemadji-Oudjiel, N., et al., *Immunohistochemical identification of type II alternatively activated dendritic macrophages (RM 3/1+3, MS-1+/-, 25F9-) in psoriatic dermis*. Arch Dermatol Res, 1996. **288**(12): p. 757-64.
52. Dustin, M.L. and D.R. Colman, *Neural and immunological synaptic relations*. Science, 2002. **298**(5594): p. 785-9.

53. Dustin, M.L. and T.A. Springer, *Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells*. J Cell Biol, 1988. **107**(1): p. 321-31.
54. Ellis, C.N., et al., *Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial*. N Engl J Med, 1991. **324**(5): p. 277-84.
55. Ellis, C.N. and G.G. Krueger, *Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes*. N Engl J Med, 2001. **345**(4): p. 248-55.
56. Enlund, F., et al., *Analysis of three suggested psoriasis susceptibility loci in a large Swedish set of families: confirmation of linkage to chromosome 6p (HLA region), and to 17q, but not to 4q*. Hum Hered, 1999. **49**(1): p. 2-8.
57. Farber, E.M., *History of the treatment of psoriasis*. J Am Acad Dermatol, 1992. **27**(4): p. 640-5.
58. Farber, E.M. and M.L. Nall, *The natural history of psoriasis in 5,600 patients*. Dermatologica, 1974. **148**(1): p. 1-18.
59. Gantner, B.N., et al., *Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2*. J Exp Med, 2003. **197**(9): p. 1107-17.
60. Gao, J.X., et al., *Perinatal blockade of b7-1 and b7-2 inhibits clonal deletion of highly pathogenic autoreactive T cells*. J Exp Med, 2002. **195**(8): p. 959-71.
61. Gearing, A.J., et al., *Cytokines in skin lesions of psoriasis*. Cytokine, 1990. **2**(1): p. 68-75.
62. Gerlini, G., et al., *CD1d is expressed on dermal dendritic cells and monocyte-derived dendritic cells*. J Invest Dermatol, 2001. **117**(3): p. 576-82.
63. Ghoreschi, K., et al., *Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease*. Nat Med, 2003. **9**(1): p. 40-6.
64. Gilhar, A., et al., *T-lymphocyte dependence of psoriatic pathology in human psoriatic skin grafted to SCID mice*. J Invest Dermatol, 1997. **109**(3): p. 283-8.
65. Gilhar, A., et al., *Psoriasis is mediated by a cutaneous defect triggered by activated immunocytes: induction of psoriasis by cells with natural killer receptors*. J Invest Dermatol, 2002. **119**(2): p. 384-91.
66. Goebeler, M., et al., *The C-X-C chemokine Mig is highly expressed in the papillae of psoriatic lesions*. J Pathol, 1998. **184**(1): p. 89-95.
67. Gottlieb, A.B., *Immunologic mechanisms in psoriasis*. J Am Acad Dermatol, 1988. **18**(6): p. 1376-80.
68. Gottlieb, A.B., et al., *Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study*. J Am Acad Dermatol, 2000. **43**(4): p. 595-604.
69. Gottlieb, S.L., et al., *Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis*. Nat Med, 1995. **1**(5): p. 442-7.
70. Grandjean, I., et al., *Are major histocompatibility complex molecules involved in the survival of naive CD4+ T cells?* J Exp Med, 2003. **198**(7): p. 1089-102.
71. Grone, A., *Keratinocytes and cytokines*. Vet Immunol Immunopathol, 2002. **88**(1-2): p. 1-12.

72. Gudjonsson, J.E., et al., *Psoriasis patients who are homozygous for the HLA-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes*. Br J Dermatol, 2003. **148**(2): p. 233-5.
73. Guilhou, J.J., J. Meynadier, and J. Clot, *New concepts in the pathogenesis of psoriasis*. Br J Dermatol, 1978. **98**(5): p. 585-92.
74. Haase, I., et al., *A role for mitogen-activated protein kinase activation by integrins in the pathogenesis of psoriasis*. J Clin Invest, 2001. **108**(4): p. 527-36.
75. Helms, C., et al., *A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis*. Nat Genet, 2003. **35**: p. 349-356.
76. Henseler, T. and E. Christophers, *Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris*. J Am Acad Dermatol, 1985. **13**(3): p. 450-6.
77. Henseler, T. and E. Christophers, *Disease concomitance in psoriasis*. J Am Acad Dermatol, 1995. **32**(6): p. 982-6.
78. Hewett, D., et al., *Identification of a psoriasis susceptibility candidate gene by linkage disequilibrium mapping with a localized single nucleotide polymorphism map*. Genomics, 2002. **79**(3): p. 305-14.
79. Hicke, B.J., et al., *DNA aptamers block L-selectin function in vivo. Inhibition of human lymphocyte trafficking in SCID mice*. J Clin Invest, 1996. **98**(12): p. 2688-92.
80. Hippocrates, et al., *Hippocratic writings*. New ed. 1978, Harmondsworth ; New York: Penguin. 380.
81. Homey, B., et al., *CCL27-CCR10 interactions regulate T cell-mediated skin inflammation*. Nat Med, 2002. **8**(2): p. 157-65.
82. Homey, B., et al., *Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis*. J Immunol, 2000. **164**(12): p. 6621-32.
83. Hong, K., et al., *IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder*. J Immunol, 1999. **162**(12): p. 7480-91.
84. Hugot, J.P., et al., *Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease*. Nature, 2001. **411**(6837): p. 599-603.
85. Ishihara, M., et al., *Genetic polymorphisms in the keratin-like S gene within the human major histocompatibility complex and association analysis on the susceptibility to psoriasis vulgaris*. Tissue Antigens, 1996. **48**(3): p. 182-6.
86. Itoh, K., et al., *Cutting edge: negative regulation of immune synapse formation by anchoring lipid raft to cytoskeleton through Cbp-EBP50-ERM assembly*. J Immunol, 2002. **168**(2): p. 541-4.
87. Jenisch, S., et al., *Corneodesmosin gene polymorphism demonstrates strong linkage disequilibrium with HLA and association with psoriasis vulgaris*. Tissue Antigens, 1999. **54**(5): p. 439-49.
88. Jones, J.L., et al., *Assessment of epidermal dendritic cell markers and T-lymphocytes in psoriasis*. J Pathol, 1994. **174**(2): p. 77-82.
89. Jowitt, S.N. and J.A. Yin, *Psoriasis and bone marrow transplantation*. Bmj, 1990. **300**(6736): p. 1398-9.

90. Kahan, B.D., *Individuality: the barrier to optimal immunosuppression*. Nat Rev Immunol, 2003. **3**(10): p. 831-8.
91. Kamarashev, J., et al., *Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept*. Dermatology, 2002. **205**(2): p. 213-6.
92. Kanai, T., et al., *Blockade of B7-H1 suppresses the development of chronic intestinal inflammation*. J Immunol, 2003. **171**(8): p. 4156-63.
93. Kanamori, H., et al., *Resolution of psoriasis following allogeneic bone marrow transplantation for chronic myelogenous leukemia: case report and review of the literature*. Am J Hematol, 2002. **71**(1): p. 41-4.
94. Kess, D., et al., *CD4(+) T cell-associated pathophysiology critically depends on CD18 gene dose effects in a murine model of psoriasis*. J Immunol, 2003. **171**(11): p. 5697-5706.
95. Kodelja, V., et al., *Differences in angiogenic potential of classically vs alternatively activated macrophages*. Immunobiology, 1997. **197**(5): p. 478-93.
96. Koo, J.Y., *Current consensus and update on psoriasis therapy: a perspective from the U.S.* J Dermatol, 1999. **26**(11): p. 723-33.
97. Krueger, G., et al., *The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey*. Arch Dermatol, 2001. **137**(3): p. 280-4.
98. Krueger, G.G., et al., *Psoriasis*. J Am Acad Dermatol, 1984. **11**(5 Pt 2): p. 937-47.
99. Krueger, J.G., *The immunologic basis for the treatment of psoriasis with new biologic agents*. J Am Acad Dermatol, 2002. **46**(1): p. 1-23; quiz 23-6.
100. Krummel, M.F. and M.M. Davis, *Dynamics of the immunological synapse: finding, establishing and solidifying a connection*. Curr Opin Immunol, 2002. **14**(1): p. 66-74.
101. Kulke, R., et al., *The CXCR receptor 2 is overexpressed in psoriatic epidermis*. J Invest Dermatol, 1998. **110**(1): p. 90-4.
102. Kupper, T.S., *Immunologic targets in psoriasis*. N Engl J Med, 2003. **349**(21): p. 1987-90.
103. Lala, S., et al., *Crohn's disease and the NOD2 gene: a role for paneth cells*. Gastroenterology, 2003. **125**(1): p. 47-57.
104. Lebwohl, M., et al., *A novel targeted T-cell modulator, efalizumab, for plaque psoriasis*. N Engl J Med, 2003. **349**(21): p. 2004-13.
105. Leonardi, C.L., et al., *Etanercept as monotherapy in patients with psoriasis*. N Engl J Med, 2003. **349**(21): p. 2014-22.
106. Leung, D.Y., et al., *A potential role for superantigens in the pathogenesis of psoriasis*. J Invest Dermatol, 1993. **100**(3): p. 225-8.
107. Li, A.G., et al., *Latent TGF β 1 overexpression in keratinocytes results in a severe psoriasis-like skin disorder*. Embo J, 2004.
108. Liang, L. and W.C. Sha, *The right place at the right time: novel B7 family members regulate effector T cell responses*. Curr Opin Immunol, 2002. **14**(3): p. 384-90.
109. Littré, A.P.E. and J.B. V. Balliere, *Hippocrates*. 1841.

110. Lomholt, G., *Psoriasis: prevalence, spontaneous course, and genetics; a census study on the prevalence of skin diseases on the Faroe Islands*. G.E.C. Gad, 1963.
111. Lowe, P.M., et al., *The endothelium in psoriasis*. Br J Dermatol, 1995. **132**(4): p. 497-505.
112. Mansbridge, J.N. and A.M. Knapp, *Changes in keratinocyte maturation during wound healing*. J Invest Dermatol, 1987. **89**(3): p. 253-63.
113. Martin, M.P., et al., *Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles*. J Immunol, 2002. **169**(6): p. 2818-22.
114. Matzinger, P., *The danger model: a renewed sense of self*. Science, 2002. **296**(5566): p. 301-5.
115. Mease, P.J., et al., *Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial*. Lancet, 2000. **356**(9227): p. 385-90.
116. Mehlis, S.L. and K.B. Gordon, *The immunology of psoriasis and biologic immunotherapy*. J Am Acad Dermatol, 2003. **49**(2 Suppl): p. S44-50.
117. Miller, G.T., et al., *Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses*. J Exp Med, 1993. **178**(1): p. 211-22.
118. Nabokov, V.V. and B. Boyd, *Speak, memory : an autobiography revisited*. 1999, New York: Alfred A. Knopf. xxxv, 268.
119. Nair, R.P., et al., *Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan*. Hum Mol Genet, 1997. **6**(8): p. 1349-56.
120. Nathan, C., *Points of control in inflammation*. Nature, 2002. **420**(6917): p. 846-52.
121. Nestle, F.O., L.A. Turka, and B.J. Nickoloff, *Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines*. J Clin Invest, 1994. **94**(1): p. 202-9.
122. Nickoloff, B.J., *The cytokine network in psoriasis*. Arch Dermatol, 1991. **127**(6): p. 871-84.
123. Nickoloff, B.J., *The immunologic and genetic basis of psoriasis*. Arch Dermatol, 1999. **135**(9): p. 1104-10.
124. Nickoloff, B.J., *Skin innate immune system in psoriasis: friend or foe?* J Clin Invest, 1999. **104**(9): p. 1161-4.
125. Nickoloff, B.J., *Characterization of lymphocyte-dependent angiogenesis using a SCID mouse: human skin model of psoriasis*. J Investig Dermatol Symp Proc, 2000. **5**(1): p. 67-73.
126. Nickoloff, B.J., *Creation of psoriatic plaques: the ultimate tumor suppressor pathway. A new model for an ancient T-cell-mediated skin disease. Viewpoint*. J Cutan Pathol, 2001. **28**(2): p. 57-64.
127. Nickoloff, B.J., et al., *Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model system*. J Dermatol Sci, 2000. **24**(3): p. 212-25.
128. Nickoloff, B.J., et al., *Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis*. Am J Pathol, 1991. **138**(1): p. 129-40.

129. Nickoloff, B.J., et al., *Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a new animal model*. Am J Pathol, 1995. **146**(3): p. 580-8.
130. Nickoloff, B.J., et al., *Recombinant gamma interferon increases the binding of peripheral blood mononuclear leukocytes and a Leu-3+ T lymphocyte clone to cultured keratinocytes and to a malignant cutaneous squamous carcinoma cell line that is blocked by antibody against the LFA-1 molecule*. J Invest Dermatol, 1988. **90**(1): p. 17-22.
131. Nickoloff, B.J., et al., *Activated keratinocytes present bacterial-derived superantigens to T lymphocytes: relevance to psoriasis*. J Dermatol Sci, 1993. **6**(2): p. 127-33.
132. Nickoloff, B.J., et al., *Discordant expression of CD28 ligands, BB-1, and B7 on keratinocytes in vitro and psoriatic cells in vivo*. Am J Pathol, 1993. **142**(4): p. 1029-40.
133. Nickoloff, B.J. and Y. Naidu, *Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skin*. J Am Acad Dermatol, 1994. **30**(4): p. 535-46.
134. Nickoloff, B.J. and T. Wrone-Smith, *Animal models of psoriasis*. Nat Med, 1997. **3**(5): p. 475-6.
135. Nickoloff, B.J. and T. Wrone-Smith, *Superantigens, autoantigens, and pathogenic T cells in psoriasis*. J Invest Dermatol, 1998. **110**(4): p. 459-60.
136. Nickoloff, B.J. and T. Wrone-Smith, *Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis*. Am J Pathol, 1999. **155**(1): p. 145-58.
137. Oestreicher, J.L., et al., *Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling*. Pharmacogenomics J, 2001. **1**(4): p. 272-87.
138. Ogura, Y., et al., *A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease*. Nature, 2001. **411**(6837): p. 603-6.
139. Ohta, Y., Y. Hamada, and K. Katsuoka, *Expression of IL-18 in psoriasis*. Arch Dermatol Res, 2001. **293**(7): p. 334-42.
140. Otto, F., M. Lubbert, and M. Stock, *Upstream and downstream targets of RUNX proteins*. J Cell Biochem, 2003. **89**(1): p. 9-18.
141. Palmer, E., *Negative selection--clearing out the bad apples from the T-cell repertoire*. Nat Rev Immunol, 2003. **3**(5): p. 383-91.
142. Prokunina, L., et al., *A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans*. Nat Genet, 2002. **32**(4): p. 666-9.
143. Rahman, P., et al., *CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis*. Am J Hum Genet, 2003. **73**(3): p. 677-81.
144. Rappersberger, K., et al., *Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated*. J Invest Dermatol, 2002. **119**(4): p. 876-87.
145. Ray, S.J., et al., *The collagen binding alpha1beta1 integrin VLA-1 regulates CD8 T cell-mediated immune protection against heterologous influenza infection*. Immunity, 2004. **20**(2): p. 167-79.

146. Raychaudhuri, S.P., et al., *Severe combined immunodeficiency mouse-human skin chimeras: a unique animal model for the study of psoriasis and cutaneous inflammation*. Br J Dermatol, 2001. **144**(5): p. 931-9.
147. Raychaudhuri, S.P., G. Rein, and E.M. Farber, *Neuropathogenesis and neuropharmacology of psoriasis*. Int J Dermatol, 1995. **34**(10): p. 685-93.
148. Reich, K., et al., *Promoter polymorphisms of the genes encoding tumor necrosis factor-alpha and interleukin-1beta are associated with different subtypes of psoriasis characterized by early and late disease onset*. J Invest Dermatol, 2002. **118**(1): p. 155-63.
149. Reitamo, S., et al., *Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial*. Br J Dermatol, 2001. **145**(3): p. 438-45.
150. Reynolds, N.J. and W.I. Al-Daraji, *Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology*. Clin Exp Dermatol, 2002. **27**(7): p. 555-61.
151. Rioux, J.D., et al., *Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease*. Nat Genet, 2001. **29**(2): p. 223-8.
152. Rodriguez, P.C., et al., *L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes*. J Immunol, 2003. **171**(3): p. 1232-9.
153. Rottman, J.B., et al., *Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris*. Lab Invest, 2001. **81**(3): p. 335-47.
154. Ruckert, R., et al., *Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis?* J Immunol, 2000. **165**(4): p. 2240-50.
155. Rudd, P.M., et al., *Glycosylation and the immune system*. Science, 2001. **291**(5512): p. 2370-6.
156. Rutgeerts, P., et al., *Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study*. Aliment Pharmacol Ther, 2003. **17**(2): p. 185-92.
157. Saiag, P., et al., *Psoriatic fibroblasts induce hyperproliferation of normal keratinocytes in a skin equivalent model in vitro*. Science, 1985. **230**(4726): p. 669-72.
158. Sakaguchi, N., et al., *Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice*. Nature, 2003. **426**(6965): p. 454-60.
159. Scheinfeld, N., *Adalimumab (HUMIRA): a review*. J Drugs Dermatol, 2003. **2**(4): p. 375-7.
160. Schiavoni, G., et al., *ICSBP is critically involved in the normal development and trafficking of Langerhans cells and dermal dendritic cells*. Blood, 2004. **103**(6): p. 2221-8.
161. Schlaak, J.F., et al., *T cells involved in psoriasis vulgaris belong to the Th1 subset*. J Invest Dermatol, 1994. **102**(2): p. 145-9.
162. Schnorr, O., C.V. Suschek, and V. Kolb-Bachofen, *The importance of cationic amino acid transporter expression in human skin*. J Invest Dermatol, 2003. **120**(6): p. 1016-22.

163. Schon, M.P., et al., *Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation*. Nat Med, 2002. **8**(4): p. 366-72.
164. Selin, L.K. and M. Cornberg, *Embedding T cells in the matrix*. Nat Med, 2004. **10**(4): p. 343-5.
165. Sigmundsdottir, H., et al., *Circulating T cells of patients with active psoriasis respond to streptococcal M-peptides sharing sequences with human epidermal keratins*. Scand J Immunol, 1997. **45**(6): p. 688-97.
166. Smith, C.A., et al., *T2 open reading frame from the Shope fibroma virus encodes a soluble form of the TNF receptor*. Biochem Biophys Res Commun, 1991. **176**(1): p. 335-42.
167. Soumelis, V., et al., *Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP*. Nat Immunol, 2002. **3**(7): p. 673-80.
168. Speckman, R.A., et al., *Novel immunoglobulin superfamily gene cluster, mapping to a region of human chromosome 17q25, linked to psoriasis susceptibility*. Hum Genet, 2003. **112**(1): p. 34-41.
169. Steed, P.M., et al., *Inactivation of TNF signaling by rationally designed dominant-negative TNF variants*. Science, 2003. **301**(5641): p. 1895-8.
170. Sticherling, M., et al., *The role of the Duffy antigen-related chemokine receptor in psoriasis vulgaris*. Cytokine, 2002. **18**(6): p. 329-33.
171. Sugai, J., et al., *Histological and immunocytochemical studies of human psoriatic lesions transplanted onto SCID mice*. J Dermatol Sci, 1998. **17**(2): p. 85-92.
172. Szabo, S.K., et al., *Identification and quantitation of interferon-gamma producing T cells in psoriatic lesions: localization to both CD4+ and CD8+ subsets*. J Invest Dermatol, 1998. **111**(6): p. 1072-8.
173. Tanaka, T., et al., *The extracellular signal-regulated kinase pathway phosphorylates AML1, an acute myeloid leukemia gene product, and potentially regulates its transactivation ability*. Mol Cell Biol, 1996. **16**(7): p. 3967-79.
174. Tazi Ahmuni, R., et al., *Novel genetic association between the corneodesmosin (MHC S) gene and susceptibility to psoriasis*. Hum Mol Genet, 1999. **8**(6): p. 1135-40.
175. Tazi-Ahmuni, R., et al., *Corneodesmosin (MHC S) gene in guttate psoriasis*. Lancet, 1999. **354**(9178): p. 597.
176. Tiilikainen, A., et al., *Psoriasis and HLA-Cw6*. Br J Dermatol, 1980. **102**(2): p. 179-84.
177. Tokuhiro, S., et al., *An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis*. Nat Genet, 2003. **35**(4): p. 341-8.
178. Tomfohrde, J., et al., *Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q*. Science, 1994. **264**(5162): p. 1141-5.
179. Travers, J.B., et al., *Epidermal HLA-DR and the enhancement of cutaneous reactivity to superantigenic toxins in psoriasis*. J Clin Invest, 1999. **104**(9): p. 1181-9.
180. Trembath, R.C., et al., *Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis*. Hum Mol Genet, 1997. **6**(5): p. 813-20.

181. Trepicchio, W.L., et al., *Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions*. J Clin Invest, 1999. **104**(11): p. 1527-37.
182. Updike, J., *Self-consciousness : memoirs*. 1st trade ed. 1989, New York: Knopf. xii, 257.
183. Uyemura, K., et al., *The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response*. J Invest Dermatol, 1993. **101**(5): p. 701-5.
184. Valdimarsson, H., et al., *Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens?* Immunol Today, 1995. **16**(3): p. 145-9.
185. Van De Kerkhof, P.C., *Neutrophils in psoriasis: cause or effect?* Clin Exp Dermatol, 2000. **25**(2): p. 165.
186. Villadsen, L.S., et al., *Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model*. J Clin Invest, 2003. **112**(10): p. 1571-80.
187. Villadsen, L.S., L. Skov, and O. Baadsgaard, *Biological response modifiers and their potential use in the treatment of inflammatory skin diseases*. Exp Dermatol, 2003. **12**(1): p. 1-10.
188. Vollmer, S., A. Menssen, and J.C. Prinz, *Dominant lesional T cell receptor rearrangements persist in relapsing psoriasis but are absent from nonlesional skin: evidence for a stable antigen-specific pathogenic T cell response in psoriasis vulgaris*. J Invest Dermatol, 2001. **117**(5): p. 1296-301.
189. Watanabe, N., et al., *Human thymic stromal lymphopoietin promotes dendritic cell-mediated CD4+ T cell homeostatic expansion*. Nat Immunol, 2004. **5**(4): p. 426-34.
190. Weinshenker, B.G., et al., *Remission of psoriatic lesions with muromonab-CD3 (orthoclone OKT3) treatment*. J Am Acad Dermatol, 1989. **20**(6): p. 1132-3.
191. Weitz-Schmidt, G., et al., *Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site*. Nat Med, 2001. **7**(6): p. 687-92.
192. Werlen, G., et al., *Signaling life and death in the thymus: timing is everything*. Science, 2003. **299**(5614): p. 1859-63.
193. Werlen, G. and E. Palmer, *The T-cell receptor signalosome: a dynamic structure with expanding complexity*. Curr Opin Immunol, 2002. **14**(3): p. 299-305.
194. Wrone-Smith, T. and B.J. Nickoloff, *Dermal injection of immunocytes induces psoriasis*. J Clin Invest, 1996. **98**(8): p. 1878-87.
195. Yabuuchi, H., et al., *Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations*. J Pharmacol Exp Ther, 1999. **289**(2): p. 768-73.
196. Yamamoto, T., et al., *Repeated subcutaneous injection of staphylococcal enterotoxin B-stimulated lymphocytes retains epidermal thickness of psoriatic skin-graft onto severe combined immunodeficient mice*. J Dermatol Sci, 1998. **17**(1): p. 8-14.
197. Yan, S.S., et al., *Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system*. Nat Med, 2003. **9**(3): p. 287-93.
198. Yang, H., H. Wang, and K.J. Tracey, *HMG-1 rediscovered as a cytokine*. Shock, 2001. **15**(4): p. 247-53.

199. Zeigler, M., et al., *Anti-CD11a ameliorates disease in the human psoriatic skin-SCID mouse transplant model: comparison of antibody to CD11a with Cyclosporin A and clobetasol propionate*. Lab Invest, 2001. **81**(9): p. 1253-61.
200. Zhang, X.J., et al., *Evidence for a major psoriasis susceptibility locus at 6p21(PSORS1) and a novel candidate region at 4q31 by genome-wide scan in Chinese hans*. J Invest Dermatol, 2002. **119**(6): p. 1361-6.
201. Zollner, T.M., et al., *Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model*. J Clin Invest, 2002. **109**(5): p. 671-9.